AtriCure (NASDAQ:ATRC) Stock: Insider Salvatore Privitera Sells 4,519 Shares

AtriCure, Inc. (NASDAQ:ATRC) insider Salvatore Privitera sold 4,519 shares of the company’s stock in a transaction on Wednesday, September 23rd. The shares were sold at an average price of $60.00, for a total transaction of $271,140.00. Following the completion of the transaction, the insider owned 142,745 shares of the company’s stock, valued at approximately $8,564,700. The trade was a 3.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Salvatore Privitera also recently made the following trade(s):

• On Tuesday, September 8th, Salvatore Privitera sold 3,657 shares of AtriCure stock. The stock was sold at an average price of $55.00, for a total transaction of $201,135.00.
• On Wednesday, September 2nd, Salvatore Privitera sold 7,763 shares of AtriCure stock. The shares were sold at an average price of $52.50, for a total transaction of $407,557.50.

AtriCure Stock Performance

NASDAQ ATRC traded up $0.81 during trading hours on Thursday, hitting $60.77. The company had a trading volume of 1,304,939 shares, compared to its average volume of 868,582. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. AtriCure, Inc. has a 1-year low of $25.36 and a 1-year high of $61.70. The company has a market cap of $3.09 billion, a PE ratio of 289.39 and a beta of 1.26. The business has a 50 day moving average of $46.26 and a 200-day moving average of $35.07.

AtriCure (NASDAQ:ATRC) last posted its earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The business had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same quarter in the previous year, the firm earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, equities research analysts expect that AtriCure, Inc. will post 0.29 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Piper Sandler increased their price objective on AtriCure from $50.00 to $60.00 and gave the company an “overweight” rating in a report on Thursday, August 27th. BTIG Research lifted their target price on shares of AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a report on Monday, August 24th. Weiss Ratings upgraded shares of AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 19th. Stifel Nicolaus set a $65.00 price target on shares of AtriCure in a research note on Thursday, September 17th. Finally, Needham & Company LLC raised their price objective on shares of AtriCure from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Wednesday, September 2nd. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, AtriCure has a consensus rating of “Moderate Buy” and an average target price of $53.30.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of ATRC. Tidal Investments LLC raised its stake in shares of AtriCure by 46.2% during the second quarter. Tidal Investments LLC now owns 19,091 shares of the medical device company’s stock worth $534,000 after purchasing an additional 6,034 shares during the last quarter. WINTON GROUP Ltd purchased a new position in AtriCure in the 2nd quarter valued at $1,002,000. Engineers Gate Manager LP grew its position in AtriCure by 12.3% in the 2nd quarter. Engineers Gate Manager LP now owns 48,160 shares of the medical device company’s stock valued at $1,348,000 after buying an additional 5,283 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new position in AtriCure in the 2nd quarter valued at $46,000. Finally, Allworth Financial LP increased its stake in AtriCure by 372.8% in the 2nd quarter. Allworth Financial LP now owns 1,527 shares of the medical device company’s stock valued at $43,000 after buying an additional 1,204 shares during the period. Institutional investors and hedge funds own 99.11% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc (NASDAQ: ATRC) is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.